Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR4640 plus febuxostat in primary hyperuricemia
CTR20192429Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruzinurad in Primary Hyperuricemia, gout, sponsored by Hengrui Therapeutics. Started Dec 2019; status: completed.
02
Drugs
ruzinurad
03
Conditions
Primary Hyperuricemiagout
Beyond the preview
Go deeper on CTR20192429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192429.